Tag: Phase
Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Park

Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Park

LONDON, August 3, 2018 /PRNewswire/ -- Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet ...

Lees verder
Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile

Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile

TAIPEI, Taiwan, July 26, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today that it has successfully completed a Phase 1 multiple ...

Lees verder
ENDOSCOPY Publishes the MORA Phase III Trial for PLENVU® (NER1006), the Only 1 Litre Peg Based Bowel Preparation[i]

ENDOSCOPY Publishes the MORA Phase III Trial for PLENVU® (NER1006), the Only 1 Litre Peg Based Bowel Preparation[i]

AMSTERDAM, July 19, 2018 /PRNewswire/ -- Norgine B.V. today announced that results from the PLENVU(R) Phase III MORA trial were published in ENDOSCOPY, a monthly peer-reviewed ...

Lees verder
McLaren Launches the Next Phase of its Pioneering esports Programme

McLaren Launches the Next Phase of its Pioneering esports Programme

LONDON, July 9, 2018 /PRNewswire/ -- The most open and inclusive racing esports tournament on the planet - global participation, multiple platforms, the biggest games. Twelve ...

Lees verder
Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published

Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published

TOKYO, June 29, 2018 /PRNewswire/ -- Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 ...

Lees verder
Norgine and Its Partner Salix Present New Data From PLENVU® (NER1006) Phase 3 Studies at Digestive Disease Week (DDW) 2018

Norgine and Its Partner Salix Present New Data From PLENVU® (NER1006) Phase 3 Studies at Digestive Disease Week (DDW) 2018

AMSTERDAM, June 5, 2018 /PRNewswire/ -- Norgine B.V. today with its partner Salix Pharmaceuticals, Ltd. ("Salix"), announced that they will present new data from phase 3 ...

Lees verder
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate

NOVATO, California, TOKYO and LONDON, May 17, 2018 /PRNewswire/ -- Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients ...

Lees verder
Semaglutide Injection Phase 2 Data Presented at ENDO Demonstrated Significant Weight Loss in Adults With Obesity

Semaglutide Injection Phase 2 Data Presented at ENDO Demonstrated Significant Weight Loss in Adults With Obesity

CHICAGO, March 19, 2018 /PRNewswire/ -- Oral session #12 Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to ...

Lees verder
Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Smal

Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Smal

DARMSTADT, Germany and NEW YORK, February 15, 2018 /PRNewswire/ -- Not intended for UK-based media Merck and Pfizer Inc. today announced results from the Phase III JAVELIN ...

Lees verder
Foresee Pharmaceuticals Announces Results from Phase 1 Clinical Studies

Foresee Pharmaceuticals Announces Results from Phase 1 Clinical Studies

Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-025, a Selective MMP-12 Inhibitor. TAIPEI, Taiwan, Dec. 4, 2017 /PRNewswire/ -- Foresee ...

Lees verder
BizPress.nl